NCT00942123

Brief Summary

Metformin is the first line drug of choice for the treatment of type II diabetes. Lactic acidosis can develop as a side effect, especially when renal failure leads to drug accumulation. Lactic acidosis is usually attributed to an abnormal inhibition of hepatic lactate clearance. Growing evidence suggest that metformin can dose-dependently inhibit hepatocyte mitochondrial function. Whether a similar effect occurs in extra-hepatic human tissues remains unknown. The investigators hypothesize that mitochondrial dysfunction occurs during metformin intoxication even in tissues other than the liver, thus contributing to the development of lactic acidosis. The aim of this study is to investigate mitochondrial integrity in circulating platelets of patients with lactic acidosis due to metformin intoxication.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 20, 2009

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
Last Updated

September 27, 2013

Status Verified

September 1, 2013

Enrollment Period

1.9 years

First QC Date

July 16, 2009

Last Update Submit

September 26, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Platelet mitochondrial respiratory chain enzyme activity

    Within 48 hours from admission to ICU

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with lactic acidosis and metformin intoxication (as documented by drug serum measurement)

You may qualify if:

  • Lactic acidosis (pH \< 7.35 or base deficit \> 5 mmol/L and lactate \> 5 mmol/L)
  • Metformin intoxication (serum drug level \> 4 mcg/mL)
  • Absence of evidence of any other condition that could primarily explain the lactic acidosis

You may not qualify if:

  • Less than 18 years of age
  • Hemoglobin \< 8 g/dL (10 g/dL if ischemic cardiac disease)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ospedale Maggiore Policlinico

Milan, MI, 20122, Italy

Location

Related Publications (1)

  • Protti A, Lecchi A, Fortunato F, Artoni A, Greppi N, Vecchio S, Fagiolari G, Moggio M, Comi GP, Mistraletti G, Lanticina B, Faraldi L, Gattinoni L. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care. 2012 Oct 3;16(5):R180. doi: 10.1186/cc11663.

MeSH Terms

Conditions

Acidosis, Lactic

Condition Hierarchy (Ancestors)

AcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2009

First Posted

July 20, 2009

Study Start

January 1, 2009

Primary Completion

December 1, 2010

Study Completion

October 1, 2011

Last Updated

September 27, 2013

Record last verified: 2013-09

Locations